Connect with us

Home

Uttar Pradesh Maati Kala Board permanent sale outlet to come up in Lucknow soon.

Published

on

Encouraged after its first venture into marketing with the Maatikala Mela- the Diwali Exhibition at Lucknow’s Khadi Bhawan, the Maatikala Board is all set to open its permanent outlet for the sale of its products in the state capital. This store in Lucknow will be the people’s one-stop store for a range of items like crockery, vessels and those of home décor, all round the year.

The Maatikala Festival in Lucknow was organised by the Mati Kala Board with the aim of promoting clay artisans of the state ahead of the occasion of Diwali. The artisans and workers were allotted stalls to sell their products that ranged from Ganesh-Lakshmi idols to diyas, pots, terracotta and decorative items. The exhibition booked an overwhelming sale of ₹50 lakh in 10 days at the venue and this helped the Board achieve its goal.

“We received a huge response. Now, there would be a permanent outlet selling clay products round the year in Lucknow,” said an official spokesman. This outlet will sell handmade products, further promoting the art of clayware and ‘Made-in-UP’ products. Other products under the ODOP (One District One Product) scheme would be added on. More details would be known once a budget is allocated for it, according to the sources.

The Mati Kala Board was established by the Uttar Pradesh Government in July 2018. Artisans making clay products for generations were given standardized dyes to make idols this time. The dyes were designed by empaneled artists. Besides ensuring the supply of clay to artisans, the board also provided training by empaneled sculptors so that artisans can use the dyes better.

Additional chief secretary MSME, also stated that more work will be done on status improvement and branding so that artisans can develop their own market. The efforts of the board are directed towards making the market competitive for artisans which will not only improve the quality of products but also get them a better price, making them self-reliant.

-With inputs from IANS

Business

447 cases of adverse effect reported,Covid-19 vaccine given to 2,24,301 beneficiaries :Govt.

Published

on

A total of 2,24,301 beneficiaries have been inoculated with COVID-19 vaccine so far, out of which only 447 adverse events following immunisation (AEFI) were reported, the Union Health Ministry said on day two of the nationwide vaccination drive on Sunday.

Addressing a press briefing, the ministry’s Additional Secretary Manohar Agnani said out of the 447 adverse events following immunisation, only three required hospitalisation.

“Today being Sunday, only six states conducted vaccination drive and in 553 sessions a total of 17,072 beneficiaries were vaccinated,” he said.

The six states where the vaccination drive was carried out on Sunday are Andhra Pradesh, Arunachal Pradesh, Karnataka, Kerala, Manipur and Tamil Nadu, he added.

Agnani said a total of 2,24,301 beneficiaries have been vaccinated till January 17 as per provisional reports, adding that 2,07,229 of them received the jabs on day one of the drive.

“A total of 447 AEFI have been reported on January 16 and 17, out of which only three required hospitalisation. Most of the AEFI reported so far are minor like fever, headache, nausea,” he said.

He said a meeting was held with all states and union territories on Sunday to review the progress of the drive, identify bottlenecks and plan corrective actions.

Prime Minister Narendra Modi rolled out the world’s largest inoculation drive against COVID-19 on Saturday and said the two vaccines being deployed will ensure a “decisive victory” for India against the pandemic.

India has approved two vaccines—Covaxin developed by Bharat Biotech and Covishield from the Oxford/AstraZeneca stable being manufactured by the Serum Institute of India—for emergency use in the country.

According to the government, the shots will be offered first to an estimated one crore healthcare workers and around two coror frontline workers, and then to persons above 50 years of age, followed by persons younger than 50 years of age with associated comorbidities. PTI

Continue Reading

Trending